Tyra Biosciences (TYRA) Return on Capital Employed (2021 - 2026)
Tyra Biosciences (TYRA) reported Return on Capital Employed of 43.56% for Q1 2026, down 1004.0% on a YoY basis from 4.82% in Q1 2025, and up 10.05% quarter-over-quarter from 48.43% in Q4 2025.
Tyra Biosciences (TYRA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Tyra Biosciences has reported Return on Capital Employed for 6 years, with the latest figure at 43.56% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1004.0% year-over-year to 43.56%; the trailing twelve-month figure through Mar 2026 stood at 43.56% (down 1004.0% YoY), and the FY2025 full-year result was 43.53%, down 634.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 43.56%, up from 48.43% in the prior quarter.
- The five-year high for Return on Capital Employed was 12.39% in Q1 2022, with the low at 48.43% in Q4 2025.
- Historically, Return on Capital Employed has averaged 29.35% across 5 years, with a median of 28.68% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 773 bps — and 2025, when it sank 1928 bps.
- Tyra Biosciences' Return on Capital Employed stood at 22.2% in 2022, then sank by 66 bps to 36.88% in 2023, then rose by 21 bps to 29.15% in 2024, then sank by 66 bps to 48.43% in 2025, then advanced by 10 bps to 43.56% in 2026.
- The last three Return on Capital Employed figures came in at 43.56% (Q1 2026), 48.43% (Q4 2025), and 42.59% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - | -43.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.56% |
| Dec 31, 2025 | -48.43% |
| Sep 30, 2025 | -42.59% |
| Jun 30, 2025 | -38.17% |
| Mar 31, 2025 | -33.52% |
| Dec 31, 2024 | -29.15% |
| Sep 30, 2024 | -26.75% |
| Jun 30, 2024 | -24.59% |
| Mar 31, 2024 | -28.68% |
| Dec 31, 2023 | -36.88% |
| Sep 30, 2023 | -29.62% |
| Jun 30, 2023 | -23.88% |
| Mar 31, 2023 | -22.74% |
| Dec 31, 2022 | -22.20% |
| Sep 30, 2022 | -19.50% |
| Jun 30, 2022 | -16.28% |
| Mar 31, 2022 | -12.39% |
| Dec 31, 2021 | -8.54% |